USD
+$0.00
(+0.00%
)At Close (As of Sep 3, 2025)
$6.39M
Market Cap
0.292
P/E Ratio
3.19
EPS
$2.42
52 Week High
$0.80
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$4.4T |
Selling General And Administrative | $3.9M |
Research And Development | $438K |
Operating Expenses | $4.4M |
Investment Income Net | - |
Net Interest Income | $1.4M |
Interest Income | $1.4M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | $23T |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $31M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | $31M |
Net Income | $31M |
Field | Value (USD) |
---|---|
Total Assets | $55M |
Total Current Assets | $22M |
Cash And Cash Equivalents At Carrying Value | $15M |
Cash And Short Term Investments | $15M |
Inventory | - |
Current Net Receivables | $3.7M |
Total Non Current Assets | $33M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $1.5M |
Intangible Assets Excluding Goodwill | $1.5M |
Goodwill | - |
Investments | - |
Long Term Investments | $22M |
Short Term Investments | $366K |
Other Current Assets | $3.1M |
Other Non Current Assets | - |
Total Liabilities | $3.3M |
Total Current Liabilities | $2.9M |
Current Accounts Payable | $399K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $363K |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $2.5M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $52M |
Treasury Stock | - |
Retained Earnings | -$85M |
Common Stock | $2.2K |
Common Stock Shares Outstanding | $7.3M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$3M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | - |
Capital Expenditures | $4 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$7M |
Cashflow From Financing | -$25M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $1.1M |
Dividend Payout Common Stock | $1.1M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$25M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $31M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$4.4T |
Selling General And Administrative | $3.9M |
Research And Development | $438K |
Operating Expenses | $4.4M |
Investment Income Net | - |
Net Interest Income | $1.4M |
Interest Income | $1.4M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | $23T |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $31M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | $31M |
Net Income | $31M |
Sector: LIFE SCIENCES
Industry: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United States. The company is headquartered in Laguna Hills, California.